Subtype
Endocrine Carcinoma
CI-CAN-00000838Explore in graph →
574 active trials16 approved drugs58 evidence items
- NCIt
- C215715
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000838Explore in graph →
Clinical trials
1,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (236)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02763579 | A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)(IMpower133) | completed | Phase 3 | 503 | Hoffmann-La RocheINDUSTRY | 21 | Jul 28, 2023 | clinicaltrials |
| NCT05496166 | The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 348 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER |
| 1 |
| May 17, 2023 |
| clinicaltrials |
| NCT00526396 | STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study(STAD-1) | unknown | Phase 3 | 160 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT03066778 | A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) | completed | Phase 3 | 453 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Oct 3, 2022 | clinicaltrials |
| NCT03711305 | Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | unknown | Phase 3 | 462 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 18, 2022 | clinicaltrials |
| NCT00286169 | Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC) | terminated | Phase 3 | 130 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01780675 | Hippocampus Avoidance PCI vs PCI(HA-PCI) | completed | Phase 3 | 168 | The Netherlands Cancer InstituteOTHER | 2 | Jan 21, 2022 | clinicaltrials |
| NCT02566993 | Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer(ATLANTIS) | completed | Phase 3 | 613 | PharmaMarINDUSTRY | 20 | Oct 28, 2021 | clinicaltrials |
| NCT00826644 | Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient(COMBAT) | completed | Phase 3 | 147 | Chonnam National University HospitalOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT03033511 | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)(MERU) | terminated | Phase 3 | 748 | AbbVieINDUSTRY | 41 | Jul 29, 2021 | clinicaltrials |
| NCT04829708 | Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy | recruiting | Phase 3 | 534 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT02990780 | Accelerated Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LS-SCLC | unknown | Phase 3 | 266 | Shanghai Chest HospitalOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04691063 | The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC. | unknown | Phase 3 | 486 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 26, 2021 | clinicaltrials |
| NCT04490421 | Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. | unknown | Phase 3 | 45 | Fuzhou General HospitalOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT04500145 | Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung Cancer | unknown | Phase 3 | 350 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT03516084 | A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer | terminated | Phase 3 | 185 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 483 | United TherapeuticsINDUSTRY | 23 | Dec 9, 2020 | clinicaltrials |
| NCT04535739 | PCI for Patients With ES-SCLC After RCT:a Prospective Randomized Study | unknown | Phase 3 | 414 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT01450761 | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | completed | Phase 3 | 1,351 | Bristol-Myers SquibbINDUSTRY | 34 | Jul 8, 2020 | clinicaltrials |
| NCT04254471 | This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients | unknown | Phase 2 / Phase 3 | 313 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04192682 | Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 40 | Changzhou Cancer Hospital of Soochow UniversityOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT00547651 | AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy | completed | Phase 3 | 637 | CelgeneINDUSTRY | 17 | Nov 6, 2019 | clinicaltrials |
| NCT04073550 | Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer | unknown | Phase 3 | 184 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 29, 2019 | clinicaltrials |
| NCT03992911 | Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma | unknown | Phase 2 / Phase 3 | 336 | Peking UniversityOTHER | 1 | Jun 20, 2019 | clinicaltrials |
| NCT02586350 | Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) | completed | Phase 2 / Phase 3 | 91 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 21, 2019 | clinicaltrials |
| NCT03239171 | Bioinformation Therapy for Lung Cancer | completed | Phase 2 / Phase 3 | 120 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT03651219 | Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer | unknown | Phase 3 | 90 | Beijing Chest HospitalOTHER | 0 | Aug 29, 2018 | clinicaltrials |
| NCT00717938 | A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer(RASTEN) | completed | Phase 3 | 390 | Lund University HospitalOTHER | 1 | Aug 25, 2017 | clinicaltrials |
| NCT00777244 | Efficacy of Adjuvant Mitotane Treatment (ADIUVO)(ADIUVO) | unknown | Phase 3 | 200 | University of Turin, ItalyOTHER | 7 | May 8, 2017 | clinicaltrials |
| NCT00320359 | Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer | completed | Phase 3 | 700 | GlaxoSmithKlineINDUSTRY | 2 | Mar 1, 2017 | clinicaltrials |
| NCT00144989 | A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC | completed | Phase 3 | 281 | Haruhiko FukudaOTHER | 1 | Sep 22, 2016 | clinicaltrials |
| NCT00094497 | Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) | completed | Phase 3 | 304 | Collaborative Group for Adrenocortical Carcinoma TreatmentOTHER | 8 | Sep 21, 2016 | clinicaltrials |
| NCT02875457 | Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin | unknown | Phase 3 | 100 | Third Military Medical UniversityOTHER | 0 | Aug 24, 2016 | clinicaltrials |
| NCT02772107 | Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 132 | Chinese PLA General HospitalOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT02738346 | SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013(CBPC) | unknown | Phase 3 | 164 | University Hospital, AngersOTHER_GOV | 1 | Apr 25, 2016 | clinicaltrials |
| NCT00930891 | Bevacizumab in Extensive Small Cell Lung Cancer(CPC) | completed | Phase 2 / Phase 3 | 143 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT00812266 | Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED) | terminated | Phase 3 | 281 | Danish Oncological Lung Cancer GroupOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT01487499 | Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)(SCLC) | terminated | Phase 3 | 4 | University of FloridaOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT00658580 | Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer | completed | Phase 3 | 361 | European Lung Cancer Working PartyOTHER | 4 | Feb 12, 2015 | clinicaltrials |
| NCT00349492 | A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer | completed | Phase 3 | 372 | Clinical Research Center for Solid Tumor, KoreaOTHER | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00043927 | Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults | completed | Phase 3 | 760 | GlaxoSmithKlineINDUSTRY | 34 | Aug 21, 2013 | clinicaltrials |
| NCT01125995 | Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer | completed | Phase 3 | 222 | Samsung Medical CenterOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT01555710 | Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) | unknown | Phase 3 | 548 | Alaunos TherapeuticsINDUSTRY | 11 | May 21, 2013 | clinicaltrials |
| NCT00276276 | Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer | completed | Phase 3 | 141 | GlaxoSmithKlineINDUSTRY | 6 | Apr 15, 2013 | clinicaltrials |
| NCT01373736 | 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors | unknown | Phase 3 | — | Vancouver Coastal HealthOTHER_GOV | 1 | Jun 15, 2011 | clinicaltrials |
| NCT00270166 | The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy | completed | Phase 3 | 201 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
| NCT00428597 | A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors | terminated | Phase 3 | 171 | PfizerINDUSTRY | 11 | Oct 11, 2010 | clinicaltrials |
Data updated 23 days agoSource updated Jul 28, 2023source: clinicaltrials